MedTrace Logo

Alkalinization by Urologists & Nephrologists

NCT03035812 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2020-07-14

No results posted yet for this study

Summary

Metabolic acidosis recovers a wide range of diseases in which an oral alkalinization could be useful. This therapeutic intervention has been said to increase extracellular volume leading to rising blood pressure. No prospective data has been published in clinical routine. Here, investigators propose to follow patients in which an oral alkalinization is indicated: blood pressure, body weight, and a clinical evaluation of the extracellular compartment will be performed at the beginning and during the follow-up of participants. The principal criterion of evaluation will be the variation in the extracellular compartment.

Conditions

  • Metabolic Acidosis
  • Nephrolithiasis
  • Extracellular Alteration
  • Blood Pressure
  • Body Weight

Interventions

DRUG

Alkali

Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)

Sponsors & Collaborators

  • Jean-Philippe Bertocchio

    lead OTHER

Principal Investigators

  • Julie Beaume, MD · Club des Jeunes Néphrologues

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2020-02-21
Completion
2020-02-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03035812 on ClinicalTrials.gov